FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 783 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid... August 12, 2025 Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib March 27, 2026 FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer February 13, 2025 Load more HOT NEWS Tratamiento agnóstico contra el cáncer: perspectiva de un experto Abnormal Collagen May Be Weak Spot for Pancreatic Cancer How Can I Get the Latest Cancer Drug? Παρακολούθηση και Φροντίδα
